Supplementation with omega-3 fatty acids in psychiatric disorders: A review of literature data

Journal of Clinical Medicine

Volumn 5, Issue 8, 2016, Pages

  Bozzatello, Paola ^a   Brignolo, Elena ^a   De Grandi, Elisa ^a   Bellino, Silvio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Attention deficit hyperactivity disorder; Borderline personality disorder; Eating disorders; Mood disorders; Omega 3 fatty acids; Polyunsaturated fatty acids; Schizophrenia; Substance use disorder; Tolerability

Indexed keywords

CLOZAPINE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPID; PLACEBO; POLYUNSATURATED FATTY ACID; QUETIAPINE; RISPERIDONE;

AGGRESSION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DEPRESSION; BORDERLINE STATE; CONTROLLED CLINICAL TRIAL (TOPIC); DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EATING DISORDER; HUMAN; IMPULSIVENESS; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS (TOPIC); MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; MULTICENTER STUDY (TOPIC); NERVE CELL MEMBRANE; OBSESSIVE COMPULSIVE DISORDER; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEROTONINERGIC NERVE CELL; SUBSTANCE ABUSE; SYSTEMATIC REVIEW (TOPIC);

EID: 85114273891     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5080067     Document Type: Review

References (134)

1. Ergas, D.; Eilat, E.; Mendlovic, S.; Sthoeger, Z.M. n-3 fatty acids and the immune system in autoimmunity. Isr. Med. Assoc. J. 2002, 4, 34–38.
2. Simopoulos, A.P. Essential fatty acids in health and chronic disease. Am. J. Clin. Nutr. 1999, 70 (Suppl. 3), 560–569.
3. Lee, S.; Gura, K.M.; Kim, S.; Arsenault, D.A.; Bistrian, B.R.; Puder, M. Current clinical applications of omega-6 and omega-3 fatty acids. Nutr. Clin. Pract. 2006, 21, 323–341.
4. Milte, C.M.; Sinn, N.; Buckley, J.D.; Coates, A.M.; Young, R.M.; Howe, P.R. Polyunsaturated fatty acids, cognition and literacy in children with ADHD with and without learning difficulties. J. Child Health Care 2011, 15, 299–311.
5. Garland, M.R.; Hallahan, B. Essential fatty acids and their role in conditions characterised by impulsivity. Int. Rev. Psychiatry 2006, 18, 99–105.
6. Ross, B.M.; Seguin, J.; Sieswerda, L.E. Omega-3 fatty acids as treatments for mental illness: Which disorder and which fatty acid? Lipids Health Dis. 2007, 6, 21.
7. Hallahan, B.; Garland, M.R. Essential fatty acids and mental health. Br. J. Psychiatry 2005, 186, 275–277.
8. Sinn, N.; Milte, C.; Howe, P.R. Oiling the brain: A review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan. Nutrients 2010, 2, 128–170.
9. Assisi, A.; Banzi, R.; Buonocore, C.; Capasso, F.; Di Muzio, V.; Michelacci, F.; Renzo, D.; Tafuri, G.; Trotta, F.; Vitocolonna, M.; et al. Fish oil and mental health: The role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. Int. Clin. Psychopharmacol. 2006, 21, 319–336.
10. De la Pressa, O.S.; Innis, S.M. Docosahexanoic and arachidonic acid prevent a decrease in dopaminergic and serotoninergic neurotrasmitters in frontal cortex caused by a linoleic and alpha-linoleic acid deficient diet in formula-fed piglets. J. Nutr. 1999, 129, 2088–2093.
11. Hamazaki, K.; Maekawa, M. Fatty acid composition of the postmortem prefrontal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder. Psychiatry Res. 2015, 227, 353–359.
12. Glen, A.I.; Glen, E.M.; Horrobin, D.F.; Vaddadi, K.S.; Spellman, M.; Morse-Fisher, N.; Ellis, K.; Skinner, F.S. A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophr. Res. 1994, 12, 53–61.
13. Horrobin, D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998, 30, 193–208.
14. Schlögelhofer, M.; Amminger, G.P.; Schaefer, M.R.; Fusar-Poli, P.; Smesny, S.; McGorry, P.; Berger, G.; Mossaheb, N. Polyunsaturated fatty acids in emerging psychosis: A safer alternative? Early Interv. Psychiatry 2014, 8, 199–208.
15. Amminger, G.P.; Schäfer, M.R.; Papageorgiou, K.; Klier, C.M.; Cotton, S.M.; Harrigan, S.M.; Mackinnon, A.; McGorry, P.D.; Berger, G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67, 146–154.
16. Markulev, C.; McGorry, P.D.; Nelson, B.; Yuen, H.P.; Schaefer, M.; Yung, A.R.; Thompson, A.; Berger, G.; Mossaheb, N.; Schlögelhofer, M.; et al. NEURAPRO-E study protocol: A multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Early Interv. Psychiatry 2015.
17. Peet, M.; Brind, J.; Ramchand, C.N.; Shah, S.; Vankar, G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001, 49, 243–251.
18. Emsley, R.; Chiliza, B.; Asmal, L.; Emsley, R.; Chiliza, B.; Asmal, L.; du Plessis, S.; Phahladira, L.; van Niekerk, E.; van Rensburg, S.J.; et al. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr. Res. 2014, 158, 230–235.
19. Peet, M.; Horrobin, D.F.; Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiat. Res. 2002, 36, 7–18.
20. Jamilian, H.; Solhi, H.; Jamilian, M. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Glob. J. Health Sci. 2014, 18, 103–108.
21. Pawełczyk, T.; Grancow-Grabka, M.; Kotlicka-Antczak, M.; Trafalska, E.; Pawełczyk, A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J. Psychiat. Res. 2016, 73, 34–44.
22. Bentsen, H.; Osnes, K.; Refsum, H. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E + C in schizophrenia. Transl. Psychiatry 2013.
23. Fenton, W.S.; Dickerson, F.; Boronow, J.; Hibbeln, J.R.; Knable, M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 2001, 158, 2071–2074.
24. Berger, G.E.; Wood, S.J.; Wellard, R.M.; Proffitt, T.M.; McConchie, M.; Amminger, G.P.; Jackson, G.D.; Velakoulis, D.; Pantelis, C.; McGorry, P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 2007, 33, 2467–2473.
25. Joy, C.B.; Mumby-Croft, R.; Joy, L.A. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst. Rev. 2006, 19, CD001257.
26. Freeman, M.P.; Hibbeln, J.R.; Wisner, K.L.; Davis, J.M.; Mischoulon, D.; Peet, M.; Keck, P.E., Jr.; Marangell, L.B.; Richardson, A.J.; Lake, J.; et al. Omega-3 fatty acids: Evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 2006, 67, 1954–1967.
27. Fusar-Poli, P.; Berger, G. Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies. J. Clin. Psychopharmacol. 2012, 32, 179–185.
28. Akter, K.; Gallo, D.A.; Martin, S.A.; Myronyuk, N.; Roberts, R.T.; Stercula, K.; Raffa, R.B. A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia. J. Clin. Pharm. Ther. 2012, 37, 132–139.
29. Emsley, R.; Myburgh, C.; Oosthuizen, P.; van Rensburg, S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 2002, 159, 1596–1598.
30. Emsley, R.; Niehaus, D.J.; Koen, L.; Oosthuizen, P.P.; Turner, H.J.; Carey, P.; Murck, H. The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial. Schizophr. Res. 2006, 84, 112–120.
31. Hibbeln, J.R.; Umhau, J.C.; Linnoila, M.; George, D.T.; Ragan, P.W.; Shoaf, S.E.; Vaughan, M.R.; Rawlings, R.; Salem, N., Jr. A replication study of violent and non-violent subjects: CSF metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Biol. Psychiatry 1998, 44, 243–249.
32. Horrobin, D.F.; Bennett, C.N. Depression and bipolar disorder: Relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukort. Essent. Fatty Acids 1999, 60, 217–234.
33. Tanskanen, A.; Hibbeln, J.R.; Hintikka, J.; Haatainen, K.; Honkalampi, K.; Viinamäki, H. Fish consumption, depression, and suicidality in a general population. Arch. Gen. Psychiatry 2001, 58, 512–513.
34. Lin, P.Y.; Huang, S.Y.; Su, K.P. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol. Psychiatry 2010, 68, 140–147.
35. Peet, M.; Horrobin, D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 2002, 59, 913–919.
36. Su, K.P.; Huang, S.Y.; Chiu, C.C.; Shen, W.W. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Neuropsychopharmacol. 2003, 13, 267–271.
37. Lespérance, F.; Frasure-Smith, N.; St-André, E.; Lespérance, F.; Frasure-Smith, N.; St-André, E.; Turecki, G.; Lespérance, P.; Wisniewski, S.R. The efficacy of omega-3 supplementation for major depression: A randomized controlled trial. J. Clin. Psychiatry 2011, 72, 1054–1062.
38. Jazayeri, S.; Tehrani-Doost, M.; Keshavarz, S.A.; Hosseini, M.; Djazayery, A.; Amini, H.; Jalali, M.; Peet, M. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust. N. Z. J. Psychiatry 2008, 42, 192–198.
39. Gertsik, L.; Poland, R.E.; Bresee, C.; Rapaport, M.H. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J. Clin. Psychopharmacol. 2012, 32, 61–64.
40. Nemets, B.; Stahl, Z.; Belmaker, R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 2002, 159, 477–479.
41. Nemets, H.; Nemets, B.; Apter, A.; Bracha, Z.; Belmaker, R.H. Omega-3 treatment of childhood depression: A controlled, double-blind pilot study. Am. J. Psychiatry 2006, 163, 1098–1100.
42. Su, K.P.; Huang, S.Y.; Chiu, T.H.; Huang, K.C.; Huang, C.L.; Chang, H.C.; Pariante, C.M. Omega-3 fatty acids for major depressive disorder during pregnancy: Results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2008, 69, 644–651.
43. Rondanelli, M.; Giacosa, A.; Opizzi, A.; Pelucchi, C.; La Vecchia, C.; Montorfano, G.; Negroni, M.; Berra, B.; Politi, P.; Rizzo, A.M. Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: Effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life. J. Nutr. Health Aging 2011, 15, 37–44.
44. Rondanelli, M.; Giacosa, A.; Opizzi, A.; Pelucchi, C.; La Vecchia, C.; Montorfano, G.; Negroni, M.; Berra, B.; Politi, P.; Rizzo, A.M. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: A double-blind, placebo-controlled, randomized clinical trial. J. Am. Coll. Nutr. 2010, 29, 55–64.
45. Rizzo, A.M.; Corsetto, P.A.; Montorfano, G.; Opizzi, A.; Faliva, M.; Giacosa, A.; Ricevuti, G.; Pelucchi, C.; Berra, B.; Rondanelli, M. Comparison between the AA/EPA ratio in depressed and non depressed elderly females: Omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters. Nutr. J. 2012, 11, 82.
46. Rees, A.M.; Austin, M.P.; Parker, G.B. Omega-3 fatty acids as a treatment for perinatal depression: Randomized double-blind placebo-controlled trial. Aust. N. Z. J. Psychiatry 2008, 42, 199–205.
47. Freeman, M.P.; Davis, M.; Sinha, P.; Wisner, K.L.; Hibbeln, J.R.; Gelenberg, A.J. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: A randomized placebo-controlled study. J. Affect Disord. 2008, 110, 142–148.
48. Marangell, L.B.; Martinez, J.M.; Zboyan, H.A.; Kertz, B.; Kim, H.F.; Puryear, L.J. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry 2003, 160, 996–998.
49. Silvers, K.M.; Woolley, C.C.; Hamilton, F.C.; Watts, P.M.; Watson, R.A. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukort. Essent. Fatty Acids 2005, 72, 211–218.
50. Grenyer, B.F.; Crowe, T.; Meyer, B.; Owen, A.J.; Grigonis-Deane, E.M.; Caputi, P.; Howe, P.R. Fish oil supplementation in the treatment of major depression: A randomised double-blind placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 1393–1396.
51. Rogers, P.J.; Appleton, K.M.; Kessler, D.; Peters, T.J.; Gunnell, D.; Hayward, R.C.; Heatherley, S.V.; Christian, L.M.; McNaughton, S.A.; Ness, A.R. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: A randomised controlled trial. Br. J. Nutr. 2008, 99, 421–431.
52. Antypa, N.; Smelt, A.H.; Strengholt, A.; Van der Does, A.J. Effects of omega-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals. J. Psychopharmacol. 2012, 26, 738–743.
53. Mischoulon, D.; Best-Popescu, C.; Laposata, M.; Merens, W.; Murakami, J.L.; Wu, S.L.; Papakostas, G.I.; Dording, C.M.; Sonawalla, S.B.; Nierenberg, A.A.; et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur. Neuropsychopharmacol. 2008, 18, 639–645.
54. Mischoulon, D.; Nierenberg, A.A.; Schettler, P.J.; Kinkead, B.L.; Fehling, K.; Martinson, M.A.; Hyman Rapaport, M. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J. Clin. Psychiat. 2015, 76, 54–61.
55. Carney, R.M.; Freedland, K.E.; Rubin, E.H.; Rich, M.W.; Steinmeyer, B.C.; Harris,W.S. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: A randomized controlled trial. JAMA 2009, 302, 1651–1657.
56. Appleton, K.M.; Rogers, P.J.; Ness, A.R. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am. J. Clin. Nutr. 2010, 91, 757–770.
57. Bloch, M.H.; Hannestad, J. Omega-3 fatty acids for the treatment of depression: Systematic review and meta-analysis. Mol. Psychiatry 2012, 17, 1272–1282.
58. Lin, P.Y.; Su, K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 2007, 68, 1056–1061.
59. Martins, J.G. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: Evidence from a meta-analysis of randomized controlled trials. J. Am. Coll. Nutr. 2009, 28, 525–542.
60. Sublette, M.E.; Ellis, S.P.; Geant, A.L.; Mann, J.J. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J. Clin. Psychiatry 2011, 72, 1577–1584.
61. Grosso, G.; Pajak, A.; Marventano, S.; Castellano, S.; Galvano, F.; Bucolo, C.; Caraci, F. Role of omega-3 fatty acids in the treatment of depressive disorders: A comprehensive meta-analysis of randomized clinical trials. PLoS ONE 2014, 9, e96905.
62. Chiu, C.C.; Huang, S.Y.; Su, K.P.; Lu, M.L.; Huang, M.C.; Chen, C.C.; Shen, W.W. Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur. Neuropsychopharmacol. 2003, 13, 99–103.
63. Frangou, S.; Lewis, M.; McCrone, P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study. Br. J. Psychiatry 2006, 188, 46–50.
64. Frangou, S.; Lewis, M.; Wollard, J.; Simmons, A. Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J. Psychopharmacol. 2007, 21, 435–439.
65. Keck, P.E., Jr.; Mintz, J.; McElroy, S.L.; Freeman, M.P.; Suppes, T.; Frye, M.A.; Altshuler, L.L.; Kupka, R.; Nolen, W.A.; Leverich, G.S.; et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol. Psychiatry 2006, 60, 1020–1022.
66. Stoll, A.L.; Severus, W.E.; Freeman, M.P.; Rueter, S.; Zboyan, H.A.; Diamond, E.; Cress, K.K.; Marangell, L.B. Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 1999, 56, 407–412.
67. Chiu, C.C.; Huang, S.Y.; Chen, C.C.; Su, K.P. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J. Clin. Psychiatry 2005, 66, 1613–1614.
68. Gracious, B.L.; Chirieac, M.C.; Costescu, S.; Finucane, T.L.; Youngstrom, E.A.; Hibbeln, J.R. Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord. 2010, 12, 142–154.
69. Murphy, B.L.; Stoll, A.L.; Harris, P.Q.; Ravichandran, C.; Babb, S.M.; Carlezon, W.A., Jr.; Cohen, B.M. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: A double-blind, randomized add-on clinical trial. J. Clin. Psychopharmacol. 2012, 32, 699–703.
70. Turnbull, T.; Cullen-Drill, M.; Smaldone, A. Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: A systematic review. Arch. Psychiat. Nurs. 2008, 22, 305–311.
71. Montgomery, P.; Richardson, A.J. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst. Rev. 2008, 2, CD005169.
72. Kraguljac, N.V.; Montori, V.M.; Pavuluri, M.; Chai, H.S.; Wilson, B.S.; Unal, S.S. Efficacy of omega-3 fatty acids in mood disorders—A systematic review and metaanalysis. Psychopharmacol. Bull. 2009, 42, 39–54.
73. Sarris, J.; Mischoulon, D.; Schweitzer, I. Omega-3 for bipolar disorder: Meta-analyses of use in mania and bipolar depression. J. Clin. Psychiatry 2012, 73, 81–86.
74. Ross, B.M. Omega-3 polyunsaturated fatty acids and anxiety disorders. Prostaglandins Leukort. Essent. Fatty Acids 2009, 81, 309–312.
75. Green, P. Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur. Neuropsychopharmacol. 2006, 16, 107–113.
76. Liu, J.J. Omega-3 Polyunsaturated fatty acid status in major depression with comorbid anxiety disorders. J. Clin. Psychiatry 2013, 74, 732–738.
77. Buydens-Branchey, L.; Branchey, M. n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J. Clin. Psychopharmacol. 2006, 26, 661–665.
78. Ravindran, A.V.; da Silva, T.L. Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: A systematic review. J. Affect Disord. 2013, 150, 707–719.
79. Fux, M.; Benjamin, J.; Nemets, B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J. Psychiat. Res. 2004, 38, 323–325.
80. Mitchell, E.A.; Aman, M.G.; Turbott, S.H.; Manku, M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin. Pediatr. (Phila.) 1987, 26, 406–411.
81. Stevens, L.; Zhang, W.; Peck, L.; Kuczek, T.; Grevstad, N.; Mahon, A.; Zentall, S.S.; Arnold, L.E.; Burgess, J.R. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003, 38, 1007–1021.
82. Burgess, J.R.; Stevens, L.; Zhang, W.; Peck, L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 2000, 71 (Suppl. 1), 327S–330S.
83. Hibbelna, J.R.; Gowb, R.V. Omega-3 fatty acid and nutrient deficits in adverse neurodevelopment and childhood behaviors. Child Adolesc. Psychiatr. Clin. N. Am. 2014, 23, 555–590.
84. Richardson, A.J.; Puri, B.K. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26, 233–239.
85. Richardson, A.J.; Montgomery, P. The Oxford-Durham study: A randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005, 115, 1360–1366.
86. Sinn, N.; Bryan, J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J. Dev. Behav. Pediatr. 2007, 28, 82–91.
87. Sinn, N.; Bryan, J.; Wilson, C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: A randomised controlled trial. Prostaglandins Leukort. Essent. Fatty Acids 2008, 78, 311–326.
88. Bélanger, S.A.; Vanasse, M.; Spahis, S.; Sylvestre, M.P.; Lippé, S.; L'heureux, F.; Ghadirian, P.; Vanasse, C.M.; Levy, E. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study. Paediatr. Child Health 2009, 14, 89–98.
89. Kirby, A.; Woodward, A.; Jackson, S.; Wang, Y.; Crawford, M.A. A double-blind, placebo-controlled study investigating the effects of omega-3 supplementation in children aged 8–10 years from a mainstream school population. Res. Dev. Disabil. 2010, 31, 718–730.
90. Perera, H.; Jeewandara, K.C.; Seneviratne, S.; Guruge, C. Combined !3 and !6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: A double-blind, placebo-controlled study. J. Child Neurol. 2012, 27, 747–753.
91. Voigt, R.G.; Llorente, A.M.; Jensen, C.L.; Fraley, J.K.; Berretta, M.C.; Heird, W.C. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J. Pediatr. 2001, 139, 189–196.
92. Hirayama, S.; Hamazaki, T.; Terasawa, K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder—A placebo-controlled double-blind study. Eur. J. Clin. Nutr. 2004, 58, 467–473.
93. Johnson, M.; Ostlund, S.; Fransson, G.; Kadesjö, B.; Gillberg, C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: A randomized placebo-controlled trial in children and adolescents. J. Atten. Disord. 2009, 12, 394–401.
94. Milte, C.M.; Parletta, N.; Buckley, J.D.; Coates, A.M.; Young, R.M.; Howe, P.R. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: A randomized controlled trial. Nutrition 2012, 28, 670–677.
95. Widenhorn-Müller, K.; Schwanda, S.; Scholz, E.; Spitzer, M.; Bode, H. Effect of supplementation with long-chain !-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): A randomized placebo-controlled intervention trial. Prostaglandins Leukort. Essent. Fatty Acids 2014, 91, 49–60.
96. Bloch, M.H.; Qawasmi, A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: Systematic review and meta-analysis. J. Am. Acad. Child Adolesc. Psychiatry 2011, 50, 991–1000.
97. Sonuga-Barke, E.J.S.; Brandeis, D.; Cortese, S.; Daley, D.; Ferrin, M.; Holtmann, M.; Stevenson, J.; Danckaerts, M.; van der Oord, S.; Döpfner, M.; et al. Nonpharmacological interventions for ADHD: Systematic review and metaanalyses of randomized controlled trials of dietary and psychological treatments. Am. J. Psychiatry 2013, 170, 275–289.
98. Gillies, D.; Sinn, J.K.h.; Lad, S.S.; Leach, M.J.; Ross, M.J. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst. Rev. 2012, 7, CD007986.
99. Gow, R.V.; Hibbeln, J.R.; Parletta, N. Current evidence and future directions for research with omega-3 fatty acids and attention deficit hyperactivity disorder. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18, 133–138.
100. Bell, J.G.; Sargent, J.R.; Tocher, D.R.; Dick, J.R. Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: A characteristic abnormality in neurodevelopmental disorders? Prostaglandins Leukort. Essent. Fatty Acids 2000, 63, 21–25.
101. Bell, J.G.; MacKinlay, E.E.; Dick, J.R.; MacDonald, D.J.; Boyle, R.M.; Glen, A.C.A. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukort. Essent. Fatty Acids 2004, 71, 201–204.
102. Vancassel, S.; Durand, G.; Barthelemy, C. Plasma fatty acid levels in autistic children. Prostaglandins Leukort. Essent. Fatty Acids 2001, 65, 1–7.
103. Belluzzi, A. n-3 fatty acids for the treatment of inflammatory bowel diseases. Proc. Nutr. Soc. 2002, 61, 391–395.
104. Horvath, K.; Perman, J.A. Autism and gastrointestinal symptoms. Curr. Gastroenterol. Rep. 2002, 4, 251–258.
105. Amminger, G.P.; Berger, G.E.; Schäfer, M.R.; Klier, C.; Friedrich, M.H.; Feucht, M. Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo controlled pilot study. Biol. Psychiatry 2007, 61, 551–553.
106. Voigt, R.G.; Mellon, M.W.; Katusic, S.K.; Weaver, A.L.; Matern, D.; Mellon, B.; Jensen, C.L.; Barbaresi, W.J. Dietary docosahexaenoic acid supplementation in children with autism. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 715–722.
107. Mankad, D.; Dupuis, A.; Smile, S.; Roberts, W.; Brian, J.; Lui, T.; Genore, L.; Zaghloul, D.; Iaboni, A.; Marcon, P.M.; et al. A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol. Autism 2015.
108. Johnson, S.M.; Hollander, E. Evidence that eicosapentaenoic acid is effective in treating autism. J. Clin. Psychiatry 2003, 64, 848–849.
109. Patrick, L.; Salik, R. The effect of essential fatty acid supplementation on language development and learning skills in autism and Asperger’s syndrome. Autism Asperger’s Dig. Available online: http://omega-research.com/researchview.php?ID=672&catid=2 (accesssed on 21 June 2016).
110. Van Elst, K.; Bruining, H.; Birtoli, B.; Terreaux, C.; Buitelaar, J.K.; Kas, M.J. Food for thought: Dietary changes in essential fatty acid ratios and the increase in autism spectrum disorders. Neurosci. Biobehav. Rev. 2014, 45, 369–378.
111. Stevens, L.J.; Zentall, S.S.; Abate, M.L.; Kuczek, T.; Burgess, J.R. Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol. Behav. 1996, 59, 915–920.
112. Buydens-Branchey, L.; Branchey, M. Association between low plasma levels of cholesterol and relapse in cocaine addicts. Psychosom. Med. 2003, 65, 86–91.
113. Hamazaki, T.; Sawazaki, S.; Itomura, M.; Asaoka, E.; Nagao, Y.; Nishimura, N.; Yazawa, K.; Kuwamori, T.; Kobayashi, M. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J. Clin. Investig. 1996, 97, 1129–1133.
114. Itomura, M.; Hamazaki, K.; Sawazaki, S.; Kobayashi, M.; Terasawa, K.; Watanabe, S.; Hamazaki, T. The effect of fish oil on physical aggression in schoolchildren—A randomized, double-blind, placebo-controlled trial. J. Nutr. Biochem. 2005, 16, 163–171.
115. Bradbury, J.; Myers, S.P.; Oliver, C. An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot). Nutr. J. 2004, 3, 20.
116. Zanarini, M.C.; Frankenburg, F.R. Omega-3 fatty acid treatment of women with borderline personality disorder: A double blind, placebo-controlled pilot study. Am. J. Psychiatry 2003, 160, 167–169.
117. Hallahan, B.; Hibblen, J.R.; Davis, J.M.; Garland, M.R. Omega-3 fatty acids supplementation in patients with recurrent self-harm: Single center double bind randomized controlled trial. Br. J. Psychiatry 2007, 190, 118–122.
118. Bellino, S.; Bozzatello, P.; Rocca, G.; Bogetto, F. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: A study of the association with valproic acid. J. Psychopharmacol. 2014, 28, 125–132.
119. Song, C.; Li, X.; Leonard, B.E.; Horrobin, D.F. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J. Lipid Res. 2003, 44, 1984–1991.
120. Buydens-Branchey, L.; Branchey, M.; Hibbeln, J.R. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 568–575.
121. Holman, R.T.; Adams, C.E.; Nelson, R.A.; Grater, S.J.; Jaskiewicz, J.A.; Johnson, S.B.; Erdman, J.W., Jr. Patients with anorexia nervosa demonstrate deficiencies of selected essential fatty acids, compensatory changes in nonessential fatty acids and decreased fluidity of plasma lipids. J. Nutr. 1995, 125, 901–907.
122. Langan, S.M.; Farrell, P.M. Vitamin E, vitamin A and essential fatty acid status of patients hospitalized for anorexia nervosa. Am. J. Clin. Nutr. 1985, 41, 1054–1056.
123. Ayton, A.K.; Azaz, A.; Horrobin, D.F. A pilot open case series of ethyl-EPA supplementation in the treatment of anorexia nervosa. Prostaglandins Leukort. Essent. Fatty Acids 2004, 71, 205–209.
124. Barbarich, N.C.; McConaha, C.W.; Halmi, K.A.; Gendall, K.; Sunday, S.R.; Gaskill, J.; la Via, M.; Frank, G.K.; Brooks, S.; Plotnicov, K.H.; et al. Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int. J. Eat. Disord. 2004, 35, 10–15.
125. Freeman, M.P.; Fava, M.; Lake, J.; Trivedi, M.H.; Wisner, K.L.; Mischoulon, D. Complementary and alternative medicine in major depressive disorder: The American Psychiatric Association Task Force report. J. Clin. Psychiatry 2010, 71, 669–681.
126. European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J. 2012, 10, 2815.
127. Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Saito, Y.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.; Hishida, H.; Itakura, H.; et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007, 369, 1090–1098.
128. Tanaka, K.; Ishikawa, Y.; Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Saito, Y.; Matsuzawa, Y.; Sasaki, J.; Oikawa, S.; Hishida, H.; et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: Subanalysis of the JELIS trial. Stroke 2008, 39, 2052–2058.
129. Hartweg, J.; Perera, R.; Montori, V.; Dinneen, S.; Neil HA and Farmer, A. Omega-3 polyunsaturated fatty acids (HUFA) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2008.
130. Hartweg, J.; Farmer, A.J.; Holman, R.R.; Neil, A. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr. Opin. Lipidol. 2009, 20, 30–38.
131. MacLean, C.H.; Mojica, W.A.; Morton, S.C.; Pencharz, J.; Hasenfeld Garland, R. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid. Rep. Technol. Assess. (Summ.) 2004, 89, 1–4.
132. Bloomer, R.J.; Larson, D.E.; Fisher-Wellman, K.H.; Galpin, A.J.; Schilling, B.K. Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: A randomized, placebo controlled, cross-over study. Lipids Health Dis. 2009.
133. VKM(Norwegian ScientificCommittee for Food Safety).Opinion of the Steering Committee of theNorwegian Scientific Committee for Food Safety: Evaluation of Negative and Positive Health Effects of n-3 Fatty Acids as Constituents of Food Supplements and Fortified Foods. Available online: http://english.vkm.no/dav/031c000d1a.pdf (accessed on 20 June 2016).
134. Farmer, A.; Montori, V.; Dinneen, S.; Clar, C. Fish oil in people with type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2001.